We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Therapeutic options for lung cancer with ALK or ROS1 (+) rearrangement
No takes yet. Share an insight, caveat, or question.
Carcereny et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: